Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects With COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 10 Apr 2012 Results published in the Respiratory Medicine.
- 26 Oct 2011 Results presented at the 77th Annual Meeting of the American College of Chest Physicians.
- 19 Oct 2011 Results will be presented at the 77th Annual Meeting of the American College of Chest Physicians, according to a GlaxoSmithKline media rease.